ArticleBMC rheumatology2026
The biologic era and pregnancy in rheumatoid arthritis: a prospective multicenter study from the Norwegian RevNatus registry.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fertility and Birth Outcomes in Rheumatoid Arthritis: A Narrative Review.Rheumatology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is known that pregnancy affects disease activity in Rheumatoid arthritis (RA), but earlier studies have shown conflicting results regarding the degree of change and the role of antibodies. Few studies have been conducted on patients with use of Tumor Necrosis Factor-α Inhibitors (TNFi) throughout pregnancy. The aims of this study were to investigate disease activity in women with RA from preconception to 12 months postpartum and assess the influence of anti-cyclic citrullinated protein antibodies (ACPA), rheumatoid factor (RF), erosive disease, and time trends.
methodsThis prospective multicenter cohort study used data from the Norwegian RevNatus registry (2007-2024). Women with RA were followed before pregnancy, each trimester, and until 12 months postpartum. We assessed disease activity using Disease Activity Score in 28 joints with C-Reactive Protein (DAS28(3)CRP). Linear mixed models were used to evaluate changes over time and interactions with ACPA, RF and erosions, and we divided pregnancies into three groups by year of delivery. Flares were defined as a change of DAS28(3)CRP > 1.2.
resultsA total of 598 pregnancies in 475 women were included. The estimated mean DAS28(3)CRP decreased from 2.39 in 2
conclusionMost women with RA maintained remission during pregnancy, but postpartum flares still occurred. Improvement was seen in pregnancies with initial high disease activity, but not in women with well managed disease. Seropositive women experienced higher disease activity and larger increase in DAS28(3)CRP postpartum. Women with pregnancies after 2020 had consistently lower disease activity compared to those who were pregnant in 2007-2019, coinciding with broader TNFi use during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.